Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 New Hypertension Drug from Novartis Approved | Contract Pharma

What are you searching for?

Sign in

New Hypertension Drug from Novartis Approved

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Novartis AG has received approval from the FDA for Tekturna, the first new class of drug in more than a decade approved for treating high blood pressure. The drug acts by inhibiting renin, an enzyme secreted primarily by the kidneys that raises blood pressure.

According to the company, it’s expected to be available later this month. According to the company, high blood pressure affects almost one billion people worldwide and is uncontrolled in about 70% of them. According to analysts, the drug may generate annual sales of approximately $1 billion.

Tekturna, which will be known as Rasilez outside the U.S., was developed with Swiss-based biopharmaceutical company, Speedel.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters